PubRank

External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma

Clinical Trial ID NCT00271050

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00271050

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 17.43
2 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 8.40
3 Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002 3.30
4 Phase I clinical trial design in cancer drug development. J Clin Oncol 2000 2.14
5 Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999 1.87
6 Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003 1.52
7 Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003 1.52
8 The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ 2003 1.32
9 Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004 1.24
10 Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000 1.10
11 Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005 1.10
12 Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2002 1.03
13 Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991 1.01
14 A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 2003 1.00
15 Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol 2003 0.96
16 Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994 0.91
17 The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002 0.87
18 History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 2003 0.86
19 Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA 2004 0.86
20 Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002 0.85
21 Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 2000 0.85
22 New treatment approaches to indolent non-Hodgkin's lymphoma. Semin Oncol 2004 0.80
23 The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991 0.78
24 Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. Int J Clin Oncol 2003 0.76
25 Positron emission tomography in the management of lymphomas: a summary. Eur J Nucl Med Mol Imaging 2003 0.75
Next 100